an honest market review of the mitochondrial peptide
MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide studied for metabolism, exercise, and bone.
One peptide, many vivid research flavors — and one honest gap. We lay out what the bone, metabolism, and exercise studies actually established, and exactly where the human evidence runs out.
The gist
Here is the MOTS-c peptide in one line: a tiny 16-amino-acid molecule your own mitochondria make, which in animal studies acts like a switch that tells cells to burn fuel more efficiently. "Mitochondria" are the parts of a cell that make energy; "peptide" just means a short chain of amino acids. In mice, MOTS-c improved blood-sugar handling, prevented diet-driven weight gain, boosted running capacity, and protected bone. The catch: almost all of that is animal and cell work. No completed human trial has tested whether injected MOTS-c does any of it in people.
What is MOTS-c?
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded not by the cell's main DNA but by a short stretch inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1 [1]. That makes it a mitochondrial-derived peptide (MDP) — a small family of signaling molecules, like humanin, written into the mitochondrion's own tiny genome rather than the nucleus. It is highly conserved across mammals, circulates in human blood, and is found in skeletal muscle; its levels rise with exercise and shift with age and metabolic state [1][4].
The founding 2015 paper described MOTS-c as a metabolic regulator: it inhibits the folate cycle (a set of reactions that supply building blocks for DNA and methylation), which causes a molecule called AICAR to pile up, which in turn switches on AMPK — AMP-activated protein kinase, the enzyme a cell uses as its low-fuel sensor [1]. When AMPK is active, cells take up more glucose and tilt toward burning fuel. Skeletal muscle is MOTS-c's main target organ [1].
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that inhibits the folate cycle, raises AICAR, and activates AMPK, improving glucose handling and insulin sensitivity in skeletal muscle in animal models [1]. Under stress it also travels from the mitochondrion into the nucleus to change which genes are switched on [3].
What the research has actually shown
Across the published record, four findings stand out as the genuinely established ones — each replicated, each cited.
Metabolism. In mice, MOTS-c prevented diet-induced obesity and both age-related and high-fat-diet-induced insulin resistance, with skeletal muscle identified as the target and AMPK as the downstream effector [1]. This is the founding result and the most-cited claim in the field.
Exercise capacity. Exercise itself induces MOTS-c in muscle and blood. When researchers injected MOTS-c into mice aged 2, 12, and 22 months, treadmill running capacity rose sharply in the oldest animals (P=0.000002), alongside gains in grip strength and gait [2]. That positioned MOTS-c as a candidate exercise mimetic — a compound that reproduces some molecular effects of physical training.
Bone. In ovariectomized mice (a standard model of post-menopausal bone loss), 5 mg/kg/day given by intraperitoneal injection for 12 weeks suppressed bone loss by blocking RANKL-driven breakdown cells, again through AMPK [5]. The MOTS-c and bone metabolism literature is the lens this review digs into.
A real human signal. In a 2024 multicenter cohort of 94 hemodialysis patients, circulating MOTS-c independently tracked with mortality and cardiovascular-event risk and sharpened a prediction model — among the strongest human association data so far, though still observational, not an intervention [14].
For the full picture, see what the research suggests MOTS-c does.
What we still do not know
The honest gap is the most important thing on this page. No completed interventional human efficacy or safety trial of injected MOTS-c exists. Every claim that exogenous MOTS-c improves metabolism, performance, or aging in people comes from cell or animal studies — predominantly mice [12]. The human data we do have are biomarker studies: blood MOTS-c is lower in obese children, tracks with insulin resistance, changes with exercise, and links to risk in dialysis patients [4][14]. Those describe the body's own MOTS-c; they do not show that a research injection reproduces the effect.
There is also no validated human pharmacokinetic profile — no measured half-life, bioavailability, or dose-response — so the rodent doses below cannot be scaled to people [4]. And because MOTS-c is sold only as a research chemical, purity and identity vary by supplier and are not regulated as pharmaceuticals. Read those caveats plainly in the MOTS-c side effects and safety context.
What are the potential benefits of MOTS-c?
In animal and cell research, MOTS-c has been associated with improved insulin sensitivity, prevention of diet-induced obesity, enhanced physical capacity, and muscle and bone preservation [1][2][5]; none of these are established human benefits, because no human efficacy trial has been completed [4].
Does MOTS-c burn fat?
In mice, MOTS-c prevented diet-induced obesity and improved adipose-tissue handling, and human biomarker studies link lower circulating MOTS-c to obesity [1][4][7]. This is associative and preclinical — it is not a demonstrated human fat-loss effect, and no human weight-loss trial exists.
How to read this review
Think of this site as a market stall where each research strand is its own brightly-labeled card. The metabolism card, the exercise card, the bone card, and the regulatory card each get their own page, and every quantitative claim is tagged to a study. Where a finding is genuinely established, we say so. Where the evidence is a single lab, a small sample, or an animal-only result, we mark it. Start with the MOTS-c dosage in the research literature for what was actually administered, or the MOTS-c study references for the source list.